Psychopathological rating scales as efficacy parameters in adult ADHD treatment investigations benchmarking instruments for international multicentre trials

Pharmacopsychiatry

Volumn 43, Issue 3, 2010, Pages 92-98

  Rosler M ^a   Retz, W ^a   Stieglitz, R D ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; DEXAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; SEROTONIN UPTAKE INHIBITOR;

ADHD RATING SCALE IV; ADULT SELF REPORT SCALE; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; BROWN ATTENTION DEFICIT DISORDER SCALE; CLINICAL PRACTICE; COGNITIVE DEFECT; COGNITIVE THERAPY; CONNERS ADULT ADHD RATING SCALE OBSERVER VERSION; DIALECTIC BEHAVIOR THERAPY; DISORIENTATION; EMOTIONAL DISORDER; HUMAN; HYPERACTIVITY; IMPULSIVENESS; INTERMETHOD COMPARISON; INTERVENTION STUDY; MEDLINE; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; PSYCHOMETRY; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; QUALITY CONTROL; RATING SCALE; REVIEW; SELF REPORT; WENDER REIMHERR ADULT ATTENTION DISORDER RATING SCALE;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BENCHMARKING; GEOGRAPHY; HUMANS; MULTICENTER STUDIES AS TOPIC; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; PSYCHOPATHOLOGY; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77952015889     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0029-1242819     Document Type: Review

References (57)

1. Adler LA, Spencer T, Faraone SV et al. Training raters to assess adult ADHD: Reliability of ratings. J Attent Disord 2005 8 121-126
2. Adler LA, Spencer T, Faraone SV et al. Validity of a pilot adult ADHD self-report scale (ASRS) to rate adult ADHD symptoms. Ann Clin Psychiatry 2006 18 145-148
3. Adler LA, Spencer DJ, Wiliams DW et al. Long-term, open-label safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: final report of a 4-year study. Pharmacopsychiatry 2007 40 247
4. Adler LA, Faraone SV, Spencer TJ et al. The reliability and validity of self- and investigator ratings of ADHD in adults. J Atten Disord 2008 11 711-718
5. Adler LA, Spencer T, Brown TE et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacology 2009 29 44-50
6. Biederman J, Mick E, Faraone S. Age-dependent decline of symptoms of attention-deficit hyperactivity disorder: Impact of remission definition and symptom type. Am J Psychiatry 2000 157 816-818
7. Biederman J, Spencer TJ, Wilens TE et al. Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectrum 2005 10 16-25 (Pubitemid 43010494)
8. Biederman J, Mick E, Surman C et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2006 59 829-835
9. Bramham J, Young S, Bickerdike A et al. Evaluation of group cognitive behavioral therapy for adults with ADHD. J Atten Disord 2008 12 434-441
10. Brotman MA, Schmajuk M, Rich BA et al. Prevalence, clinical correlates, and longitudinal course of severe mood dysregulation in children. Biol Psychiatry 2006 60 991-997
11. Brown TE. Brown attention-deficit disorder scales for adolescents and adults Psychological Corporation, USA 1966
12. Conners CK, Erhardt D, Sparrow E. CAARS Adult ADHD Rating Scales Technical Manual MHS New York 1999
13. Dorego MF, Canevaro L, Kuzis G et al. A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit hyperactivity disorder: Preliminary findings. J Neuropsychiatry Clin Neurosci 2002 14 289-295
14. DuPaul G, Power T, Anastopoulos A, etal. ADHD Rating Scale-IV: Checklist, norms, and clinical interpretation Guilford, New York 1998
15. EMEA European Medicinal Agency. Guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD) (draft) 2009 www.emea.europa.eu
16. Faraone S, Spencer T, Aleardi M et al. Meta-analysis of the efficacy of methylpheridate for treating adult attention deficit hyperactivity disorder. J Clin Psychopharmacol 2004 24 24-29
17. Gibbins C, Weiss M. Clinical recommendations in current practice guidelines in diagnosis and treatment of ADHD in adults. Cur Psychiatry Rep 2007 9 420-426
18. Jain U, Hechtman L, Weiss M et al. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention deficit hyperactivity disorder: Results of a double-blind. placebo-controlled crossover study. J Clin Psychiatry 2007 68 268-277
19. Kessler RC, Adler L, Ames M et al. The World Health Organization adult ADHD self-report scale (ASRS): a short screening scale for use in the general population. Psychol Medicine 2005 35 245-256
20. Kooij JJ, Burger H, Boonstra AM et al. Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychol Medicine 2004 34 973-982
21. Kuperman S, Perry PJ, Gaffney GR et al. Bupropion SR vs methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Ann Clin Psychiatry 2001 13 129-133
22. McGough JJ, Barkley RA. Diagnostic controversies in adult attention deficit hyperactivity disorder. Am J Psychiatry 2004 161 1948-1956
23. McGough JJ, McCracken JT. Adult attention deficit hyperactivity disorder: Moving beyond DSM-IV. Am J Psychiatry 2006 163 1673-1675
24. Medori R, Ramos-Quidroga J, Casas M et al. A randomized placebo-controlled trial of three fixed dosages of prolonged-release OROS-methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2008 15 981-989
25. Michelson D, Adler L, Spencer T et al. Atomoxetine in adults with ADHD. Two randomized, placebo-controlled studies. Biol Psychiatry 2003 15 112-120
26. Murphy KR, Adler LA. Assessing attention-deficit/hyperactivity disorder in adults: Focus on rating scales. J Clin Psychiatry 2004 65 (Suppl 3) 12-17
27. Murphy P, Schachar R. Use of self-ratings in the assessment of symptoms of attention deficit hyperactivity disorder in adults. Am J Psychiatry 2000 157 1156-1159
28. Paterson R, Douglas C, Hallmayer J et al. A randomized, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder. Aust N Z J Psychiatry 1999 33 494-502
29. Philipsen A, Richter H, Peters J. Structured group psychotherapy in adults with attention deficit hyperactivity disorder: Results of an open multicenter study. J Nerv Ment Dis 2007 195 1013-1019
30. Philipsen A, Trott GE, Rösler M et al. Open-label extension trial of the safety and tolerability of OROS methylphenidate in adults with ADHD long acting methylphenidate in adult ADHD (Lamda) trial. Pharmacopsychiatry 2007 40 247-248
31. Reimherr FW, Marchant BK, Strong RE et al. Emotional dysregulation in adult ADHD and response to atomoxetine. Biol Psychiatry 2005 58 125-131
32. Reimherr FW, Williams ED, Strong RE et al. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 2007 68 93-101
33. Rösler M, Retz W, Retz-Junginger P et al. Instrumente zur Diagnostik der Aufmerksamkeitsdefizit-/Hyperaktivittsstörung im Erwachsenenalter: Selbstbeurteilungsskala (ADHS-SB) und Diagnose Checkliste (ADHS-CL). Nervenarzt 2004 75 888-895
34. Rösler M, Retz W, Thome J et al. Psychopathological rating scales for diagnostic use in adults with attention deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci 2006 256 (Suppl 1) 3-11
35. Rösler M, Trott GE, Philipsen A et al. Efficacy and safety of OROS methylphenidate in adults with ADHD: the long acting methylphenidate in adult ADHD (Lamda) trial. Pharmacopsychiatry 2007 40 248
36. Rösler M, Retz-Junginger P, Retz W, etal. HASE Homburger ADHS Skalen fr Erwachsene Hogrefe, Göttingen 2008a
37. Rösler M, Retz W, Retz-Junginger P et al. ADHS-Diagnose bei Erwachsenen. Nervenarzt 2008 79 320-327
38. Rösler M, Fischer R, Ammer R et al. A randomized, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiat Clin Neurosci 2009 258 120-129
39. Roessner V, Becker A, Rothenberger A et al. A cross-cultural comparison between samples of Brazilian and German children with ADHD/HD using the Child Behavior Checklist. Eur Arch Psychiat Clin Neurosci 2007 257 352-359
40. Rostain AL, Ramsay JR. A combined treatment approach for adults with ADHD-results of an open study of 43 patients. J Attention Disorder 2006 10 150-159
41. Safren SA, Otto MW, Sprich S et al. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Ther 2005 43 831-842
42. Spencer T, Adler LA. Diagnostic approaches to adult ADHD. Prim Psychiatry 2004 11 49-56
43. Spencer T, Biederman J, Wilens TE et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2001 58 775-782
44. Spencer T, Biederman J, Wilens T et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiat 2005 57 456-463
45. Spencer TJ, Adler LA, McGough JJ et al. Efficacy and safety of dexmeythlphenidate extended-release capsules in adults with attention-deficit/ hyperactivity disorder. Biol Psychiatry 2007 61 1380-1387
46. Spencer TJ, Adler LA, Weisler RH et al. Triple-bead mixed amphetamine salts (SPD465) a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD A randomized, double-blind, multicenter, placebo-controlled study. J Clin Psychiatry 2008 69 1437-1448
47. Stevenson CS, Whitmont S, Bornholt L et al. A cognitive remediation programme for adults with attention deficit hyperactivity disorder. Aust N Z J Psychiatry 2002 36 610-661
48. Stieglitz RD, Rösler M. Diagnosis of attention-deficit/hyperactivity disorder (ADHD) in adults. Z Psychiat Psychol Psychother 2006 54 87-98
49. Taylor F, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacology 2000 10 311-320
50. Walcott CM, Landau S. The relation between disinhibition and emotional regulation in boys with attention-deficit/hyperactivity disorder. J Clin Child Adolesc Psychol 2004 33 772-782
51. Weisler RH, Biederman J, Spencer TJ et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: A randomised, controlled trial. CNS Spectrum 2005 11 625-639
52. Weiss M, Hechtman L, The adult ADHD research group. A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry 2006 67 611-619
53. Wender PH. Attention-deficit hyperactivity disorder in adults Oxford, New York 1995
54. Wilens TE, Spencer TJ, Biederman J et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001 158 282-288
55. Wilens TE, Verlinden MH, Adler LA et al. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit hyperactivity disorder in adults: results of a pilot study. Biol Psychiatry 2006 59 1065-1070
56. Woo BS, Rey JM. The validity of the DSM-IV subtypes of attention-deficit/hyperactivity disorder. Aust NZ J Psychiatry 2005 39 344-353
57. Zylowska L, Ackerman DL, Yang MH et al. Mindfulness meditation training in adults and adolescents with ADHD: A feasibility study. J Attent Disord 2008 11 737-746